Dr. Hidalgo Medina on Treatment Considerations in Pancreatic Cancer


In Partnership With:

Manuel Hidalgo Medina, MD, PhD, discusses treatment considerations in pancreatic cancer.

Manuel Hidalgo Medina, MD, PhD, chief, Division of Hematology and Medical Oncology, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses treatment considerations in pancreatic cancer.

It is important to consider sequencing strategies when devising a treatment plan for patients with pancreatic cancer, says Hidalgo Medina. By sequencing systemic chemotherapy, patients will have the opportunity to derive the maximum benefit from treatment. In addition to sequencing strategies, it is also critical to evaluate BRCA1/2 status, as the presence of the mutation could indicate that the patient is eligible to receive a PARP inhibitor, he adds.

Finally, it is important to remember that patients with reduced performance status can still derive benefit from systemic chemotherapy, says Hidalgo Medina. These patients should not be deemed ineligible for intensive therapy; rather, providers should aim to reduce their symptoms, which would potentially make them eligible for systemic therapy, concludes Hidalgo Medina.

Related Videos
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Akriti Jain, MD
Samer A. Srour, MB ChB, MS